Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606773 | 0.89 | SLC2A1 (0.71) | SLC2A1ALOX15P2RY12SMN1; SMN2POLB | |
| SCHEMBL6607801 | 0.84 | SLC2A1 (0.64) | SLC2A1ALOX15ACHEAPPP2RY12 | |
| SCHEMBL6607938 | 0.81 | SLC2A1 (0.62) | SLC2A1ALOX15ACHEAPPP2RY12 | |
| SCHEMBL7805323 | 0.78 | SLC2A1 (0.69) | SLC2A1ALOX15APPSMN1; SMN2POLB | |
| SCHEMBL6622619 | 0.78 | SLC2A1 (0.65) | SLC2A1ALOX15ACHEAPPP2RY12 | |
| SCHEMBL7805470 | 0.75 | SLC2A1 (0.65) | SLC2A1ALOX15ACHEAPPP2RY12 | |
| SCHEMBL6607445 | 0.74 | SLC2A1 (0.54) | SLC2A1ALOX15ACHEAPPP2RY12 | |
| SCHEMBL13036676 | 0.74 | ALOX15 (0.60) | SLC2A1ALOX15ACHEAPPSMN1; SMN2 | |
| SCHEMBL6607915 | 0.74 | SLC2A1 (0.62) | SLC2A1ALOX15APPSMN1; SMN2POLB | |
| SCHEMBL6594249 | 0.73 | SLC2A1 (0.58) | SLC2A1ALOX15P2RY12POLBPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818655-B2 | 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| EP-1359915-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040063757-A1 | Urotensin-ll receptor antagonists | SMITHKLINEE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1359915-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002058702-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063757-A1 | Urotensin-ll receptor antagonists | UTS2R, PLAUR, SCTR | SLC2A1 3284/4885ALOX15 2175/4885ACHE 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.